 Ann Kulungowski
Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 7 | 2020 | 40 | 3.640 |
Why?
| | Lymphatic Abnormalities | 3 | 2020 | 14 | 2.050 |
Why?
| | Sclerotherapy | 2 | 2018 | 15 | 1.380 |
Why?
| | Secondary Prevention | 2 | 2018 | 250 | 1.190 |
Why?
| | Hemangioma | 5 | 2016 | 37 | 1.020 |
Why?
| | Wounds, Nonpenetrating | 3 | 2019 | 282 | 0.860 |
Why?
| | Surgery Department, Hospital | 2 | 2016 | 21 | 0.790 |
Why?
| | Vertebral Artery | 1 | 2019 | 27 | 0.760 |
Why?
| | Hypovolemia | 1 | 2019 | 15 | 0.760 |
Why?
| | Pediatric Emergency Medicine | 1 | 2019 | 27 | 0.760 |
Why?
| | Carotid Artery Injuries | 1 | 2019 | 44 | 0.750 |
Why?
| | Liver Neoplasms | 5 | 2015 | 457 | 0.740 |
Why?
| | Doxycycline | 1 | 2018 | 57 | 0.730 |
Why?
| | Medical Errors | 1 | 2019 | 101 | 0.700 |
Why?
| | Craniocerebral Trauma | 1 | 2019 | 153 | 0.670 |
Why?
| | Infant | 18 | 2022 | 8065 | 0.650 |
Why?
| | Sclerosing Solutions | 1 | 2016 | 4 | 0.640 |
Why?
| | Hospital Rapid Response Team | 1 | 2016 | 18 | 0.640 |
Why?
| | Intestines | 1 | 2019 | 306 | 0.620 |
Why?
| | Veins | 1 | 2016 | 67 | 0.610 |
Why?
| | Bevacizumab | 1 | 2016 | 126 | 0.610 |
Why?
| | Patient Safety | 1 | 2019 | 303 | 0.590 |
Why?
| | Ileal Diseases | 1 | 2014 | 13 | 0.570 |
Why?
| | Interferon-alpha | 1 | 2016 | 209 | 0.560 |
Why?
| | Rectum | 2 | 2015 | 149 | 0.520 |
Why?
| | Infant, Newborn | 14 | 2022 | 5014 | 0.510 |
Why?
| | Child Abuse | 1 | 2019 | 522 | 0.510 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 491 | 0.510 |
Why?
| | Receptors, Somatotropin | 1 | 2012 | 9 | 0.490 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2845 | 0.480 |
Why?
| | Blood Transfusion | 4 | 2022 | 293 | 0.470 |
Why?
| | Crohn Disease | 1 | 2014 | 167 | 0.460 |
Why?
| | Genital Neoplasms, Male | 1 | 2011 | 6 | 0.450 |
Why?
| | Genitalia, Male | 1 | 2011 | 12 | 0.450 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 15 | 0.450 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 100 | 0.440 |
Why?
| | Receptors, Androgen | 1 | 2012 | 118 | 0.440 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 574 | 0.440 |
Why?
| | Disease Management | 1 | 2015 | 603 | 0.420 |
Why?
| | Mesenteric Veins | 1 | 2010 | 9 | 0.420 |
Why?
| | Registries | 3 | 2015 | 1866 | 0.420 |
Why?
| | Blood Vessels | 1 | 2012 | 191 | 0.410 |
Why?
| | Child, Preschool | 13 | 2019 | 9618 | 0.410 |
Why?
| | HELLP Syndrome | 1 | 2009 | 3 | 0.410 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 336 | 0.400 |
Why?
| | Portal Vein | 1 | 2010 | 89 | 0.390 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 389 | 0.380 |
Why?
| | Child | 16 | 2022 | 17710 | 0.380 |
Why?
| | Venous Thrombosis | 1 | 2010 | 134 | 0.360 |
Why?
| | Retrospective Studies | 13 | 2022 | 11544 | 0.350 |
Why?
| | Bone Transplantation | 3 | 2012 | 110 | 0.310 |
Why?
| | Adolescent | 12 | 2019 | 18580 | 0.300 |
Why?
| | Anticoagulants | 1 | 2010 | 534 | 0.300 |
Why?
| | Hemorrhage | 1 | 2009 | 585 | 0.300 |
Why?
| | Recurrence | 2 | 2018 | 975 | 0.270 |
Why?
| | Phlebography | 2 | 2016 | 39 | 0.260 |
Why?
| | Humans | 30 | 2022 | 113890 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2018 | 9100 | 0.250 |
Why?
| | Craniotomy | 3 | 2012 | 64 | 0.250 |
Why?
| | Lymphedema | 2 | 2014 | 21 | 0.240 |
Why?
| | Radiologists | 1 | 2022 | 28 | 0.240 |
Why?
| | Noonan Syndrome | 1 | 2022 | 16 | 0.240 |
Why?
| | Parietal Bone | 2 | 2012 | 10 | 0.230 |
Why?
| | Frontal Bone | 2 | 2012 | 14 | 0.230 |
Why?
| | Congenital Abnormalities | 1 | 2022 | 69 | 0.220 |
Why?
| | Male | 21 | 2018 | 60623 | 0.220 |
Why?
| | Incidence | 4 | 2022 | 2449 | 0.220 |
Why?
| | Rabbits | 4 | 2016 | 799 | 0.220 |
Why?
| | Professional Role | 1 | 2022 | 162 | 0.210 |
Why?
| | Female | 18 | 2018 | 62822 | 0.200 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 295 | 0.190 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.190 |
Why?
| | Skin Neoplasms | 2 | 2016 | 754 | 0.190 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 13 | 0.190 |
Why?
| | Duodenal Obstruction | 1 | 2018 | 5 | 0.190 |
Why?
| | Duodenostomy | 1 | 2018 | 4 | 0.190 |
Why?
| | Duodenum | 1 | 2018 | 54 | 0.180 |
Why?
| | Thoracotomy | 1 | 2018 | 88 | 0.170 |
Why?
| | Thoracic Injuries | 1 | 2018 | 57 | 0.170 |
Why?
| | Wounds, Penetrating | 1 | 2018 | 79 | 0.170 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 149 | 0.160 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2016 | 13 | 0.160 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4927 | 0.160 |
Why?
| | Shock, Hemorrhagic | 1 | 2019 | 254 | 0.160 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 49 | 0.160 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 11 | 0.150 |
Why?
| | Hypotension | 1 | 2016 | 123 | 0.150 |
Why?
| | Pyloric Stenosis, Hypertrophic | 1 | 2015 | 7 | 0.150 |
Why?
| | Shock | 1 | 2016 | 90 | 0.150 |
Why?
| | Catheters, Indwelling | 1 | 2015 | 87 | 0.150 |
Why?
| | Drug Carriers | 1 | 2016 | 126 | 0.140 |
Why?
| | Hirschsprung Disease | 1 | 2015 | 53 | 0.140 |
Why?
| | Risk Assessment | 3 | 2015 | 3177 | 0.140 |
Why?
| | Peritoneal Dialysis | 1 | 2015 | 78 | 0.140 |
Why?
| | Genital Diseases, Male | 1 | 2014 | 14 | 0.140 |
Why?
| | Penis | 1 | 2014 | 29 | 0.140 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2014 | 24 | 0.140 |
Why?
| | Scrotum | 1 | 2014 | 24 | 0.140 |
Why?
| | Laparoscopy | 1 | 2018 | 392 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 227 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2022 | 899 | 0.130 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 89 | 0.130 |
Why?
| | Gastroenterology | 1 | 2015 | 151 | 0.130 |
Why?
| | Postoperative Care | 1 | 2015 | 234 | 0.130 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 159 | 0.130 |
Why?
| | Neonatal Screening | 1 | 2015 | 182 | 0.130 |
Why?
| | Global Health | 1 | 2015 | 347 | 0.120 |
Why?
| | Arteriovenous Malformations | 1 | 2012 | 21 | 0.120 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1415 | 0.120 |
Why?
| | Hamartoma | 1 | 2012 | 17 | 0.120 |
Why?
| | Lipomatosis | 1 | 2011 | 3 | 0.120 |
Why?
| | Cheek | 1 | 2011 | 15 | 0.120 |
Why?
| | Prospective Studies | 3 | 2012 | 6292 | 0.120 |
Why?
| | Hemangioendothelioma | 1 | 2011 | 12 | 0.120 |
Why?
| | alpha-Fetoproteins | 1 | 2011 | 35 | 0.110 |
Why?
| | Bone Resorption | 1 | 2012 | 90 | 0.110 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 54 | 0.110 |
Why?
| | Young Adult | 6 | 2015 | 10971 | 0.110 |
Why?
| | Biomarkers | 2 | 2012 | 3468 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2185 | 0.110 |
Why?
| | Rare Diseases | 1 | 2011 | 82 | 0.110 |
Why?
| | Ligation | 1 | 2010 | 81 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2032 | 0.100 |
Why?
| | Length of Stay | 1 | 2015 | 1066 | 0.100 |
Why?
| | Skull | 1 | 2010 | 139 | 0.100 |
Why?
| | Prostheses and Implants | 1 | 2010 | 157 | 0.090 |
Why?
| | Osteogenesis | 1 | 2010 | 210 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2016 | 3850 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1217 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1763 | 0.080 |
Why?
| | Pediatrics | 1 | 2015 | 1048 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1792 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3146 | 0.080 |
Why?
| | Colorado | 1 | 2016 | 4484 | 0.080 |
Why?
| | Databases, Factual | 1 | 2011 | 1169 | 0.080 |
Why?
| | Adult | 4 | 2012 | 31958 | 0.070 |
Why?
| | Risk Factors | 3 | 2022 | 9036 | 0.070 |
Why?
| | Massachusetts | 2 | 2014 | 125 | 0.070 |
Why?
| | Prognosis | 1 | 2011 | 3539 | 0.060 |
Why?
| | Liver | 1 | 2011 | 1825 | 0.060 |
Why?
| | Splenectomy | 1 | 2022 | 50 | 0.060 |
Why?
| | Perioperative Period | 1 | 2022 | 45 | 0.060 |
Why?
| | Esophageal Atresia | 1 | 2022 | 21 | 0.060 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 31 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 125 | 0.060 |
Why?
| | X-Ray Microtomography | 2 | 2012 | 61 | 0.060 |
Why?
| | Pyrimidinones | 1 | 2022 | 95 | 0.060 |
Why?
| | Pyridones | 1 | 2022 | 113 | 0.050 |
Why?
| | Survival Rate | 2 | 2015 | 1852 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 459 | 0.050 |
Why?
| | Spleen | 1 | 2022 | 535 | 0.050 |
Why?
| | Animals | 4 | 2016 | 34695 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 130 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 113 | 0.040 |
Why?
| | Pregnancy | 1 | 2009 | 5237 | 0.040 |
Why?
| | Heart Diseases | 1 | 2022 | 369 | 0.040 |
Why?
| | Middle Aged | 3 | 2014 | 28776 | 0.040 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 35 | 0.040 |
Why?
| | Dialysis Solutions | 1 | 2015 | 24 | 0.040 |
Why?
| | Peritonitis | 1 | 2015 | 79 | 0.040 |
Why?
| | Resuscitation | 1 | 2018 | 304 | 0.040 |
Why?
| | Anemia | 1 | 2016 | 163 | 0.040 |
Why?
| | Constipation | 1 | 2015 | 69 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 193 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 189 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1931 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 345 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2016 | 547 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 153 | 0.030 |
Why?
| | Heart Arrest | 1 | 2018 | 321 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 2015 | 152 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 243 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 263 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 273 | 0.030 |
Why?
| | Gestational Age | 1 | 2015 | 761 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 883 | 0.030 |
Why?
| | Biopsy | 1 | 2015 | 1042 | 0.030 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2011 | 13 | 0.030 |
Why?
| | Osseointegration | 1 | 2011 | 22 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1593 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 48 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1215 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 65 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2011 | 79 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 86 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 431 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 125 | 0.030 |
Why?
| | Comorbidity | 1 | 2015 | 1631 | 0.030 |
Why?
| | Logistic Models | 1 | 2015 | 2051 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1997 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 396 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 493 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 600 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 229 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 384 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1088 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 855 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3271 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 521 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 938 | 0.020 |
Why?
| | Reconstructive Surgical Procedures | 1 | 2010 | 252 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3403 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 4993 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 7011 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2564 | 0.010 |
Why?
| | Aged | 1 | 2014 | 20127 | 0.010 |
Why?
|
|
Kulungowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|